Biktarvy
E409696
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Biktarvy canonical | 2 |
| bictegravir | 1 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
HIV-1 treatment
ⓘ
antiretroviral medication ⓘ fixed-dose combination drug ⓘ |
| approvalYear | 2018 ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| ATCCode | J05AR15 ⓘ |
| belongsToTherapeuticArea |
HIV/AIDS
ⓘ
infectious diseases ⓘ |
| containsDrugClass |
integrase strand transfer inhibitor
ⓘ
nucleoside reverse transcriptase inhibitor ⓘ nucleotide reverse transcriptase inhibitor ⓘ |
| contraindicatedWith |
strong inducers of CYP3A
ⓘ
strong inducers of UGT1A1 ⓘ |
| countryOfFirstApproval |
United States of America
ⓘ
surface form:
United States
|
| developedBy |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| dosageForm | film-coated tablet ⓘ |
| hasActiveIngredient |
Biktarvy
self-linksurface differs
ⓘ
surface form:
bictegravir
emtricitabine ⓘ tenofovir alafenamide ⓘ |
| hasGenericName | bictegravir/emtricitabine/tenofovir alafenamide ⓘ |
| hasSideEffect |
diarrhea
ⓘ
headache ⓘ nausea ⓘ |
| hasTradeName | Biktarvy self-link ⓘ |
| hasWarning |
risk of acute exacerbation of hepatitis B after discontinuation
ⓘ
risk of lactic acidosis ⓘ risk of severe hepatomegaly with steatosis ⓘ |
| indicatedFor |
treatment of HIV-1 infection in adults
ⓘ
treatment of HIV-1 infection in pediatric patients ⓘ |
| intendedUse | complete regimen for HIV-1 infection ⓘ |
| isCombinationOf |
bictegravir
ⓘ
Descovy ⓘ
surface form:
emtricitabine
tenofovir alafenamide ⓘ |
| isCompleteRegimen | true ⓘ |
| isOnceDailyRegimen | true ⓘ |
| marketedBy |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| metabolismInvolves |
CYP3A
ⓘ
UGT1A1 ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| regulatoryStatus | prescription only ⓘ |
| requiresMonitoring |
hepatic function
ⓘ
renal function ⓘ |
| routeOfAdministration | oral ⓘ |
| target |
HIV-1 integrase
ⓘ
HIV-1 reverse transcriptase ⓘ |
| treats | HIV-1 infection ⓘ |
| typicalDosingFrequency | once daily ⓘ |
| usedInCombinationTherapy | no additional antiretrovirals required ⓘ |
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Gilead Sciences
this entity surface form:
bictegravir